drugset / Trial / NCT07655804

Subcutaneous Calcitonin in Acute Herpes Zoster

NCT07655804

Phase 3 Recruiting 168 enrolled Tanta University
RandomizedParallel-groupDouble-blindPrevention

Summary

This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.

Timeline

Start
2026-07-01
Primary completion
2027-04-01
Completion
2027-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcitonin Protein / enzyme biologic 100 iu Subcutaneous

Indications